Reviews/Anti CGRP Antibodies/Comparable CGRP antibody efficacy
Episodic Migraine · CGRP-EMR-03 · v2
The claim says the four approved anti-CGRP antibodies work about equally well in people whose migraine is episodic rather than chronic. The corpus does contain supportive signals: several real-world clinics in different countries found the injected antibodies roughly interchangeable [18][28][29], and one study that gave the three injected drugs side by side found no overall difference in how many patients responded [38]. But there is no randomised trial that pits the drugs directly against each other, the fourth drug (eptinezumab) never appears in any comparison, and most of the 'similar' findings come from chronic or mixed patients rather than the episodic group the claim is about. In the one episodic-specific result, fremanezumab actually came out ahead [38]. The panel judged the general idea of class-level similarity reasonably reproduced, but the specific episodic, all-four-drug wording not cleanly supported.
Three independent real-world cohorts report no between-drug efficacy difference across erenumab, galcanezumab and fremanezumab: [18] found 'all three anti-CGRP mAbs were similarly effective', [28] found 'The reduction in migraine days was similar for the different anti-CGRP treatments', and [29] found 'Effectiveness appeared similar among the three CGRP mAbs.' The single direct head-to-head [38] reported 'there was no difference in the response rate overall' across the three injected antibodies. Placebo-controlled episodic-migraine trials place the magnitudes in a comparable band — eptinezumab reduced monthly migraine days by -3.9 (100 mg) and -4.3 (300 mg) [2], ALD403 by -5.6 [26], and erenumab by -5.3 at five years [8]. None of this is randomised head-to-head evidence, and most cross-drug data is drawn from chronic or mixed populations. The contested point: The evidence divides on the episodic population the claim names: the general 'no difference' signal is overwhelmingly chronic or mixed, and the one explicitly episodic comparison in [38] found 'fremanezumab had a higher response rate at 12-month follow-up when compared to galcanezumab and erenumab.' Whether observational 'no difference' reflects true equivalence or limited power is also unresolved, and eptinezumab is absent from every comparison [2][26].
All 38 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Anti CGRP Antibodies, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
No randomised head-to-head trial exists in the corpus. Comparability rests entirely on observational cohorts ([18],[28],[29],[38]) subject to confounding by indication and prescriber channelling; 'no difference' in observational data can reflect limited power rather than true equivalence.
The claim is episodic-specific, but the explicit episodic signal contradicts it: in [38]'s high-frequency episodic subgroup 'fremanezumab had a higher response rate at 12-month follow-up when compared to galcanezumab and erenumab.' The 'similar' findings of [18],[28],[29] are predominantly chronic or mixed populations.
Where it remains uncertain. The claim is episodic-specific, yet [38]'s high-frequency episodic subgroup found fremanezumab superior, and eptinezumab appears in no comparison at all [2][26].
Aleatory
Response to a given antibody varies widely patient to patient (super-responders to non-responders), so cohort averages can read as 'similar' while individual drug choice still matters.
The load-bearing papers from a corpus of 38, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Eptinezumab episodic-migraine effect size for indirect cross-trial comparison.
“Eptinezumab 100 mg and 300 mg met the primary endpoint, significantly reducing MMDs across weeks 1-12 compared with placebo (30 mg, -4.0; 100 mg, -3.9, p = 0.0182; 300 mg, -4.3; placebo, -3.2, p = 0.0001).”
Panel auditInternal validity: high · scope of inference: Eptinezumab doses vs placebo for prevention of episodic migraine in adults.Key limitations: placebo comparison only · no head-to-head antibody contrast
Erenumab episodic-migraine magnitude, broadly similar band to eptinezumab trials.
“Mean (standard error) change in MMDs from baseline of 8.7 (0.2) days was -5.3 (0.3) days; an average reduction of 62.3% at year 5.”
Panel auditInternal validity: medium · scope of inference: Long-term erenumab efficacy/safety in episodic migraine.Key limitations: single antibody · open-label uncontrolled · attrition
Cross-drug comparability signal (though in resistant chronic migraine).
“In the overall population, all three anti-CGRP mAbs were similarly effective and dropouts were 17.2%.”
Panel auditInternal validity: medium · scope of inference: Three anti-CGRP mAbs in resistant chronic migraine under Italian reimbursement criteria.Key limitations: chronic migraine, not episodic · observational · unequal drug group sizes
Direct head-to-head of the three subcutaneous mAbs showing overall comparability.
“There was no statistical difference in monthly migraine days, intensity, or symptomatic medication intake per month at the different follow-ups. Moreover, there was no difference in the response rate overall.”
Panel auditInternal validity: medium · scope of inference: Comparative effectiveness of the three approved antibodies in chronic and high-frequency episodic migraineurs.Key limitations: subgroup finding without stated significance · overall migraine-day measures showed no difference (mixed signal) · observational, moderate sample
4 of 38 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Class-level comparability is reasonably reproduced in observational data, keeping the claim above Doubtful, but the episodic-specific, all-four-drug wording is not carried cleanly given the absence of head-to-head RCTs, the eptinezumab gap, and a contradictory episodic subgroup result.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No randomised head-to-head in episodic migraine. Every comparative finding in the corpus is observational [18][28][29][38], vulnerable to confounding by indication and prescriber channelling. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised, blinded, active-comparator trial of the approved antibodies with an episodic-migraine primary population and a pre-specified equivalence or non-inferiority margin on monthly migraine days.
Open question: Do the approved anti-CGRP antibodies differ in efficacy specifically in episodic migraine when compared directly? Why it is still open: Only observational cross-drug data exists [18][28][29][38], and the single episodic subgroup result [38] favoured fremanezumab rather than showing equivalence.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19